cisplatin and pemetrexed

DRUG2 trials

Sponsors

Sun Yat-sen University, University of Chicago

Conditions

Carcinoma，Non-Small-Cell LungPleural Mesothelioma

Phase 1

A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma

TerminatedNCT02707666

University of ChicagoPleural Mesothelioma

Start: 2016-02-25End: 2023-04-24Updated: 2024-07-31

Phase 3

A Prospective Multi-center Phase III Randomized Controlled Trial

Sun Yat-sen UniversityCarcinoma，Non-Small-Cell Lung

Start: 2015-08-31End: 2022-12-31Target: 293Updated: 2022-02-25

Related Papers

Nedaplatin plus pemetrexed or cisplatin plus pemetrexed as first-line chemotherapy for EGFR/ALK-negative advanced lung adenocarcinoma (NACA): A multicenter, open-label, non-inferiority, randomized, phase III trial.

Journal of Clinical Oncology2022-06-01